News & Updates

Show Multimedia Only

Study offers clues on which patients may safely stop HBV therapy

15 Dec 2021 by

Think twice before withdrawing HBV treatment. Not all patients can safely discontinue nucleos(t)ide analogue (NA) therapy as shown in the retrospective RETRACT-B study of patients from Europe, North America, and Asia.

Study offers clues on which patients may safely stop HBV therapy

15 Dec 2021

Increased serum iron may hint at HCC risk in NAFLD patients

07 Dec 2021 by

Increased serum iron or transferrin saturation levels in individuals with non-alcoholic fatty liver disease (NAFLD) may point to an increased risk of hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting Digital Experience™.

Increased serum iron may hint at HCC risk in NAFLD patients

07 Dec 2021

Switching to TAF helps improve virologic response in HBV patients in real world

06 Dec 2021 by

Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.

Switching to TAF helps improve virologic response in HBV patients in real world

06 Dec 2021

Interim findings boost therapeutic potential of lanifibranor for NASH

06 Dec 2021 by

The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.

Interim findings boost therapeutic potential of lanifibranor for NASH

06 Dec 2021

Non-overweight NAFLD patients have poor liver transplant outcomes

03 Dec 2021 by

Non-overweight patients with non-alcoholic fatty liver disease (NAFLD) have an elevated risk of all-cause mortality following liver transplant and are also more likely to be removed from the liver transplant waitlist compared with obese/overweight patients, according to a study presented at The Liver Meeting Digital Experience™.

Non-overweight NAFLD patients have poor liver transplant outcomes

03 Dec 2021

Two-dose hep-B vaccine more seroprotective than three-dose regimen in chronic liver disease patients

02 Dec 2021 by

In a pooled post hoc analysis of three phase III trials, a novel two-dose hepatitis B (hep-B) vaccine regimen trumped the traditional three-dose regimen in inducing seroprotection in patients with chronic liver disease (CLD).

Two-dose hep-B vaccine more seroprotective than three-dose regimen in chronic liver disease patients

02 Dec 2021

More than half of NASH patients respond to HVPG-guided NSBB prophylaxis

30 Nov 2021

Hepatic venous pressure gradient (HVPG)-guided prophylaxis with non-selective beta blockers (NSBB) seems to be reasonably effective in patients with nonalcoholic steatohepatitis (NASH), eliciting responses from around half of this population, a recent study has found.

More than half of NASH patients respond to HVPG-guided NSBB prophylaxis

30 Nov 2021

Phase II data underscores lanifibranor potential for NASH

30 Nov 2021 by

In the phase IIb NATIVE* trial, the pan-PPAR** agonist lanifibranor demonstrated histologic benefits for patients with nonalcoholic steatohepatitis (NASH).

Phase II data underscores lanifibranor potential for NASH

30 Nov 2021

Statins not only good for the heart, but also the liver

27 Nov 2021 by

Statins can help preserve liver function in patients with chronic liver disease, according to two studies presented at AASLD 2021— showing that not only are statins protective for the heart, but also for the liver.

Statins not only good for the heart, but also the liver

27 Nov 2021

PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD

27 Nov 2021

Plasma levels of PRO-C3, a serological biomarker for the detection of the formation of type III collagen, can act as a good indicator of disease activity and fibrosis in nonalcoholic fatty liver disease (NAFLD), a recent study has found.

PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD

27 Nov 2021

News & Updates

Filter by Specialty:

Specialty:

Study offers clues on which patients may safely stop HBV therapy

Study offers clues on which patients may safely stop HBV therapy

Increased serum iron may hint at HCC risk in NAFLD patients

Increased serum iron may hint at HCC risk in NAFLD patients

Switching to TAF helps improve virologic response in HBV patients in real world

Switching to TAF helps improve virologic response in HBV patients in real world

Interim findings boost therapeutic potential of lanifibranor for NASH

Interim findings boost therapeutic potential of lanifibranor for NASH

Non-overweight NAFLD patients have poor liver transplant outcomes

Non-overweight NAFLD patients have poor liver transplant outcomes

Two-dose hep-B vaccine more seroprotective than three-dose regimen in chronic liver disease patients

Two-dose hep-B vaccine more seroprotective than three-dose regimen in chronic liver disease patients

More than half of NASH patients respond to HVPG-guided NSBB prophylaxis

More than half of NASH patients respond to HVPG-guided NSBB prophylaxis

Phase II data underscores lanifibranor potential for NASH

Phase II data underscores lanifibranor potential for NASH

Statins not only good for the heart, but also the liver

Statins not only good for the heart, but also the liver

PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD

PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD